CVS Health Corporation
NYSE:CVSMedical - Healthcare Plans
-$0.59 today
- Market cap
- $104.08B
- Beta
- 0.62
- P/E (TTM)
- 42.8
- EPS (TTM)
- $2.30
- Dividend yield
- 2.70%
Volume 17.19M
Average 8.19M
CVS Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
CVS Health CorporationNYSE: CVS
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $1.13B fell 3.8% year over year, behind the -2.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.0% from the prior quarter. Over 3 fiscal years it compounded at +2.9% a year.
Context
- Depreciation & amortization amounted to 1.1% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -3.8% toward the trailing-twelve-month pace of -2.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 4.61B USD
- Year-over-year change
- +0.2%
- 4-year CAGR
- +0.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.61B | +0.2% |
| FY2024 | 2024-12-31 | 4.6B | +5.3% |
| FY2023 | 2023-12-31 | 4.37B | +3.4% |
| FY2022 | 2022-12-31 | 4.22B | -5.8% |
| FY2021 | 2021-12-31 | 4.49B | — |
Depreciation & Amortization vs competitors
How CVS compares with its peers on the latest reported figures
- CVS's LTM Jun 2026 depreciation & amortization of $4.52B is the highest of the 9 companies compared; the peer median is $1B.
- Its year-over-year change of -2.4% is the 5th highest of 9, against a peer median of -2.0%.
- Depreciation & amortization amounts to 1.1% of revenue for CVS, versus a peer median of 0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $4.52B | -2.4% | +2.9% | 1.1% | |
| LTM Sep 2026 | $4.26B | -0.6% | +8.7% | 0.9% | |
| LTM Sep 2026 | $2.89B | +7.2% | -1.9% | 1.0% | |
| LTM Sep 2026 | $1.49B | -3.2% | -2.6% | 0.7% | |
| LTM Jun 2026 | $1.25B | -0.8% | -6.4% | 0.6% | |
| LTM Sep 2026 | $763M | -12.3% | -0.8% | 0.5% | |
| LTM Sep 2026 | $161M | -19.1% | +3.5% | 0.4% | |
| LTM Mar 2026 | $30.69M | +7.1% | +20.4% | 0.7% | |
| LTM Jun 2026 | $28.24M | -7.2% | +23.6% | 0.2% | |
| Peer median (excluding CVS) | $1B | -2.0% | +1.3% | 0.7% | |
Competitors are the stored peer set for CVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 292.11B | 322.47B | 357.78B | 372.81B | 402.07B |
| Cost of Revenue | 239.99B | 267.97B | 303.35B | 321.41B | 346.71B |
| Gross Profit | 52.12B | 54.5B | 54.43B | 51.4B | 55.36B |
| Gross Margin | 17.8% | 16.9% | 15.2% | 13.8% | 13.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 41.23B | 0 |
| Operating Expenses | 38.81B | 46.55B | 40.69B | 42.89B | 44.98B |
| Depreciation & Amortization | 4.49B | 4.22B | 4.37B | 4.6B | 4.61B |
| EBITDA | 17.53B | 12.35B | 18.2B | 13.68B | 9.86B |
| EBITDA Margin | 6.0% | 3.8% | 5.1% | 3.7% | 2.5% |
| Operating Income | 13.31B | 7.95B | 13.74B | 8.52B | 10.39B |
| Operating Margin | 4.6% | 2.5% | 3.8% | 2.3% | 2.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2.5B | 2.29B | 2.66B | 2.96B | 3.12B |
| Other Income / Expenses | (2.77B) | (2.12B) | (2.57B) | (2.37B) | (8.25B) |
| Income Before Tax | 10.54B | 5.84B | 11.17B | 6.15B | 2.14B |
| Pre-Tax Margin | 3.6% | 1.8% | 3.1% | 1.6% | 0.5% |
| Income Tax Expense | 2.55B | 1.51B | 2.81B | 1.56B | 408M |
| Net Income | 8B | 4.31B | 8.34B | 4.61B | 1.77B |
| Net Margin | 2.7% | 1.3% | 2.3% | 1.2% | 0.4% |
| EPS (Basic) | 6.00 | 3.29 | 6.49 | 3.66 | 1.40 |
| EPS (Diluted) | 5.95 | 3.26 | 6.47 | 3.66 | 1.39 |
| Weighted Avg Shares | 1.32B | 1.31B | 1.29B | 1.26B | 1.27B |
| Weighted Avg Shares (Diluted) | 1.33B | 1.32B | 1.29B | 1.26B | 1.27B |
CVS Health Corporation
NYSE:CVS
Intrinsic Alpha fair value
Locked
Current Price
$81.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.